Lokon Pharma AB

FDA Grants Fast Track Designation to LOAd703 for Pancreatic Cancer Treatment

4 months ago

• The FDA has granted Fast Track designation to LOAd703, an oncolytic adenovirus, for treating patients with pancreatic cancer, expediting its development and review. • LOAd703 is being evaluated in a phase 1/2 trial (LOKON001) in combination with chemotherapy for unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). • Early results from the trial showed an overall response rate of 44% and a disease control rate of 94% among efficacy-evaluable patients treated with LOAd703. • The Fast Track designation will allow Lokon Pharma to have more frequent interactions with the FDA, potentially accelerating LOAd703's availability to patients.